Advertisement
Advertisement
ITRM
Iterum Therapeutics plc Ordinary Share
0.17
USDSponsored
0.00
+2.50%
Mar 25, 13:44 UTC -4
Closed
After-Market
0.18
0.00
+2.33%
ITRM Earnings Reports
Positive Surprise Ratio
ITRM beat 17 of 29 last estimates.
59%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$1.43M
/-$0.10
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q1 25 (Revenue/ EPS)
--
/-28.57%
Iterum Therapeutics plc Ordinary Share earnings per share and revenue
On Mar 12, 2026, ITRM reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -0.14 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 515.10 thousand, with a --% difference. The market reacted with a +5.89% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of -0.10 USD, with revenue projected to reach 1.43 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Talphera, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
Relmada Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.14
Actual
-$0.28
Surprise
-103.08%
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
FAQ
What were Iterum Therapeutics plc Ordinary Share's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Iterum Therapeutics plc Ordinary Share reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Iterum Therapeutics plc Ordinary Share's Q4 2025 earnings?
The stock price moved up 5.89%, changed from $0.29 before the earnings release to $0.30 the day after.
When is Iterum Therapeutics plc Ordinary Share expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Iterum Therapeutics plc Ordinary Share's next earnings report?
Based on 3
analysts, Iterum Therapeutics plc Ordinary Share is expected to report EPS of -$0.10 and revenue of $1.43M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement